uPath PR (1E2) image analysis, Breast
Use left and right arrow keys to scroll between the tabs
uPath whole slide image analysis algorithms
An intelligent and advanced digital pathology solution requires artificial intelligence-based image analysis tools that empower pathologists to confidently and objectively assess whole tissue slide images.
The uPath PR (1E2) image analysis, Breast* algorithm is an adjunctive computer-assisted tool that identifies PR positive and negative tumor cells within a pathologist-annotated viable tumor region in images of formalin-fixed, paraffin-embedded neoplastic breast tissue.
Advancing pathology workflows for true efficiency
Unlock the power of an integrated solution that automates key tasks, offering accuracy, consistency and confidence in results.
Integrated and ready-to-use
Validated for use with the CONFIRM PR (1E2) Antibody and navify Digital Pathology software.
Quick and automated
Pathologist-trained deep learning algorithm quickly identifies PR tumor cell positivity.
Accurate, consistent and confident
Actionable assessment of slide images that are objective and reproducible.1
Unlock the benefits of uPath PR (1E2) image analysis, Breast*
- Enhanced accuracy with pathologist-trained deep learning algorithm which results in objective and reproducible scoring of slide images scanned on a VENTANA slide scanner and stained with CONFIRM PR (1E2) Rabbit Monoclonal Primary Antibody1
- Fully embedded into navify® Digital Pathology software to enable seamless viewing, aligning, syncing, sharing, and reporting
- Speed up time to results for user-defined regions of interest with whole slide analysis (WSA) and automated pre-computing of the slide image prior to pathologist assessment1
- Quickly identify PR tumor cell positivity and stratifies stained cells by stain intensity
- A clear visual overlay highlights tumor cells with and without nuclear staining for easy reference
Specifications
| Scanner | VENTANA DP 200 and VENTANA DP 600 slide scanners |
| Software | navify Digital Pathology |
| Algorithm | uPath PR (1E2) image analysis, Breast* |
| Assay | CONFIRM PR (1E2) Rabbit Monoclonal Primary Antibody |
| Tissue Type | Breast |
| Scoring | Percent PR positivity |
| Regulatory status | Research Use Only (RUO) |
Maximize the potential of your digital pathology laboratory
The Roche Digital Pathology solution comprises high-performance hardware, software and uPath whole slide image analysis algorithms, and works in integrated harmony with the full Roche diagnostic portfolio for an end-to-end experience that enhances pathology workflows.
*For research use only. Not for use in diagnostic procedures.
Roche Digital Pathology Dx, including navify Digital Pathology, is intended for specific clinical applications and is for research and educational use for other applications. Please review the product labeling for compliance before utilization.
NAVIFY and VENTANA and UPATH are trademarks of Roche. Other product names and trademarks are the property of their respective owners.
Reference:
- Kapadia, M., et al. (2022). "Abstract P1-02-17: Artificial intelligence-based whole slide scoring of nuclear breast cancer IHC markers Ki67, ER, and PR matches performance of manual clinical scoring." Cancer Research 82(4_Supplement): P1-02-17. https://doi.org/10.1158/1538-7445.SABCS21-P1-02-17.
